SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-037240
Filing Date
2022-10-14
Accepted
2022-10-14 16:33:49
Documents
13
Period of Report
2022-10-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10042946_8k.htm   iXBRL 8-K 29818
2 EXHIBIT 10.1 brhc10042946_10-1.htm EX-10.1 76635
  Complete submission text file 0001140361-22-037240.txt   262284

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btx-20221008.xsd EX-101.SCH 3872
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20221008_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20221008_pre.xml EX-101.PRE 16050
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10042946_8k_htm.xml XML 4245
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221311672
SIC: 2834 Pharmaceutical Preparations